Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study

Journal:
The Lancet Oncology
Published:
DOI:
10.1016/s1470-2045(25)00140-8
Affiliations:
20
Authors:
19
Go to article
Institutions Authors Share
Jazz Pharmaceuticals PLC, United States of America (USA)
3.000000
 0.16
Vall d'Hebron University Hospital (HUVH), ICS, Spain
2.000000
 0.11
Sarah Cannon Research Institute (SCRI), United States of America (USA)
1.000000
 0.05
South Texas Accelerated Research Therapeutics, LLC (START), United States of America (USA)
1.000000
 0.05
Sir Mortimer B. Davis Jewish General Hospital (SMBD JGH), Canada
1.000000
 0.05
Hospital General Universitario de Elche, Spain
1.000000
 0.05
The Ottawa Hospital (TOH), Canada
1.000000
 0.05
Sunnybrook Health Sciences Centre, U of T, Canada
1.000000
 0.05
Hospital Clínico Universitario de Valencia, Spain
1.000000
 0.05
Arthur J.E. Child Comprehensive Cancer Centre (Arthur Child), AHS, Canada
1.000000
 0.05
Fred Hutchinson Cancer Center, United States of America (USA)
1.000000
 0.05
University of Washington (UW), United States of America (USA)
1.000000
 0.05
Virgen del Rocío University Hospital, Spain
1.000000
 0.05
Saint Luke's Health System, United States of America (USA)
0.500000
 0.03
University of Missouri-Kansas City (UMKC), United States of America (USA)
0.500000
 0.03
Institute of Biomedical Research in Malaga (IBIMA), Spain
0.500000
 0.03
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain
0.500000
 0.03
IOB Institute of Oncology, Spain
0.333333
 0.02
Hospital Beata María Ana, Spain
0.333333
 0.02
Hospital Universitario Ramón y Cajal, Spain
0.333333
 0.02
Interested in Oncology and Carcinogenesis?